Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 vs Dacarbazine in Metastatic Melanoma
NCT00864253Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2009
- Primary completion
- Jun 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of nab-paclitaxel in Malignant Melanoma (MM), sponsored by Celgene Corporation. Started Apr 2009; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00864253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00864253.